Clinical Trial Update: Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating prophylactic lisinopril for anthracycline-induced cardiomyopathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiomyopathy
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Lisinopril (Lisinopril)

Snippet

Sponsor: Ascension Health | Conditions: Cardiomyopathy Due to Drug, Heart Failure, Systolic | Phase 4 | Status: WITHDRAWN